Joss R, Cerny T
Onkologische Abteilung, Kantonsspital Luzern.
Schweiz Med Wochenschr. 1990 May 12;120(19):693-703.
Tumor markers can be used for screening, diagnosis, planning and monitoring of therapy, for early detection of relapse and for psychological reasons. Unfortunately none of the currently available tumor markers can be used for all these purposes. An ever increasing number of tumor markers can be determined; however, the advantage for the individual patient's management is less obvious. We therefore critically review the routine use of some tumor markers such as CEA, AFP, beta-HCG, LDH, CA-125, CA 19-9, prostate acid phosphatase, prostate specific antigen and CA 15-3. The use of tumor markers requires a sound knowledge of the biology of the marker, the neoplastic disease and the available treatment. When tumor markers do not add new information and have no diagnostic or therapeutic consequences, their use becomes an expensive medical nonsense!
肿瘤标志物可用于筛查、诊断、治疗方案制定与监测、复发的早期检测以及出于心理方面的原因。遗憾的是,目前可用的肿瘤标志物中没有一种能用于所有这些目的。可检测的肿瘤标志物数量不断增加;然而,对个体患者管理的益处却不那么明显。因此,我们批判性地审视了一些肿瘤标志物的常规应用,如癌胚抗原(CEA)、甲胎蛋白(AFP)、β-人绒毛膜促性腺激素(β-HCG)、乳酸脱氢酶(LDH)、癌抗原125(CA-125)、癌抗原19-9(CA 19-9)、前列腺酸性磷酸酶、前列腺特异性抗原以及癌抗原15-3(CA 15-3)。肿瘤标志物的使用需要对标志物的生物学特性、肿瘤性疾病以及可用治疗方法有充分的了解。当肿瘤标志物不能提供新信息且没有诊断或治疗意义时,其使用就变成了昂贵的医疗无意义行为!